Why ImmunityBio Stock Slumped on Monday
Key Points
It sent the company a warning letter about a TV ad and a podcast episode about Anktiva.
ImmunityBio sounded a contrite note in response.
- 10 stocks we like better than ImmunityBio ›
Cancer-focused biotech ImmunityBio (NASDAQ: IBRX) hasn't been in the good graces of a top regulator lately, and the latest development in that story on Monday was discouraging for investors. Numerous shareholders sold out of the stock to sink it by slightly over 3% that trading session.
Peeved about promotional materials
That regulator is the U.S. Food and Drug Administration (FDA). In mid-March, it sent ImmunityBio a warning letter stating that the biotech's recent promotional materials for cancer immunotherapy drug Anktiva were "false or misleading."
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Specifically, the FDA's warning covers a TV ad, in addition to a podcast episode rather provocatively titled "Is the FDA BLOCKING Life Saving Cancer Treatments?" The main subject of both is, of course, Anktiva.
Despite what has to be considered the accusatory title of the podcast, the FDA approved Anktiva as a treatment for adults with BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) nearly two years ago.
On Monday, ImmunityBio said it filed a formal response to the warning letter. It stressed that the TV ad was never aired or otherwise publicly disseminated. Further, the company said, it has taken concrete measures to satisfy the regulator's concerns, "including the removal of the identified podcast from its corporate website and requesting its removal from third-party platforms."
Someone made a misstep
That dampened investor sentiment for two reasons. First, it made ImmunityBio look rash and sensationalistic, particularly with that podcast title. Second, it indicated a near-complete retreat in the face of the regulator's warning; this move felt weak to begin with and made the promotional campaign seem ill-considered and a waste of always-precious company time and resources.
Every management team makes mistakes, so I don't think it's right to overly punish ImmunityBio for this clear misfire. Still, I'd keep a cautious eye on how the company manages its marketing going forward. It's never wise or useful to get on the wrong side of a regulator, particular if it's green-lighted one of your products in the recent past.
Should you buy stock in ImmunityBio right now?
Before you buy stock in ImmunityBio, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ImmunityBio wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $532,066!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,087,496!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 6, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
